Duration:
1 minute and 33 seconds
Views:
37
Seattle Genetics Incorporated - symbol SGEN - reported that the U.S. FDA has granted accelerated approval of ADCETRIS. ADCETRIS is the first approved by the FDA for Hodgkin lymphoma in more than 30 years, and provides a new therapeutic alternative for Hodgkin lymphoma and systemic anaplastic large cell lymphoma in these settings.